[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT07332416":3,"trial-entities:NCT07332416":72,"trial-summary:NCT07332416":43},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":6,"overall_status":7,"completion_date":8,"status_verified_date":9,"last_update_date":10,"start_date":11,"sponsor_name":12,"lead_sponsor_class":13,"has_dmc":14,"brief_summary":15,"detailed_description":16,"conditions":17,"keywords":19,"study_type":23,"primary_purpose":24,"phases":25,"enrollment_info":27,"interventions":30,"primary_outcomes":35,"secondary_outcomes":40,"sex":41,"minimum_age":42,"maximum_age":43,"healthy_volunteers":14,"eligibility_criteria":44,"std_ages":53,"locations":56,"central_contacts":65,"overall_officials":66,"references":70,"see_also_links":71},"NCT07332416","IRB00143138","Pilot Study of Continuous Glucose Monitoring for Postpartum Glucose Screening","ENROLLING_BY_INVITATION","2027-01","2026-05","2026-07-10","2026-07-06","Wake Forest University Health Sciences","OTHER",false,"The oral glucose tolerance test (OGTT) is the standard of care in the postpartum period to screen patients with gestational diabetes mellitus (GDM) for persistent dysglycemia. However, most patients find it burdensome and dread having to do it. Adherence rates are low (18-61%), impeding initiation of follow-up care to improve diabetes-related outcomes in subsequent pregnancies and long-term.","Continuous glucose monitoring (CGM) is an appealing alternative to the OGTT because it is a low-burden, fully remote, comprehensive assessment of glycemic status. Emerging data suggest that CGM is superior to the OGTT in identifying persistent dysglycemia at 2-5 months postpartum, and preferable to the OGTT among women willing to complete both assessments in the context of a research study. This study proposes a feasibility study of postpartum CGM among patients who do not complete the standard postpartum OGTT. The study will offer CGM in a telehealth (fully remote) context to determine if it can increase adherence to postpartum glycemic screening in real-world settings. This study will (a) evaluate uptake of CGM screening, (b) characterize patients who complete CGM, complete the OGTT, or do not complete screening, and (c) monitor initiation of follow-up care after abnormal results.",[18],"Gestational Diabetes",[20,21,22],"Continuous glucose monitoring","Postpartum glucose screening","Dysglycemia","INTERVENTIONAL","SCREENING",[26],"NA",{"count":28,"type":29},1300,"ESTIMATED",[31],{"type":13,"name":32,"description":33,"armGroupLabels":34},"Continuous glucose monitoring for 14 days using the Freestyle LibrePro by Abbott","Postpartum CGM",[33],[36],{"measure":37,"description":38,"timeFrame":39},"Continuous Glucose Monitor (CGM) uptake - Percentage of CGM-eligible patients","Percentage of CGM-eligible patients that return a used CGM sensor","20 weeks postpartum",[],"FEMALE","18 Years",null,{"inclusion":45,"exclusion":49,"raw_text":52},[46,47,48],"12-16 weeks postpartum","Gestational diabetes Mellitus (GDM) diagnosis in most recent pregnancy","Oral Glucose Tolerance Test (OGTT) order placed in the medical record",[50,51],"Pre-gestational diabetes","Non-English language","Inclusion Criteria:\n\n* 12-16 weeks postpartum\n* Gestational diabetes Mellitus (GDM) diagnosis in most recent pregnancy\n* Oral Glucose Tolerance Test (OGTT) order placed in the medical record\n\nExclusion Criteria:\n\n* Pre-gestational diabetes\n* Non-English language",[54,55],"ADULT","OLDER_ADULT",[57],{"facility":12,"city":58,"state":59,"zip":60,"country":61,"geoPoint":62},"Winston-Salem","North Carolina","27157","United States",{"lat":63,"lon":64},36.09986,-80.24422,[],[67],{"name":68,"affiliation":12,"role":69},"Katherine A Sauder, MD","PRINCIPAL_INVESTIGATOR",[],[],{"nct_id":4,"conditions":73,"biomarkers":74},[22,18],[]]